Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Centessa Pharmaceuticals plc ADR shares valued at $200,000 were sold by Accardi Mario Alberto on Oct 27 ’25. At $25.00 per share, Accardi Mario Alberto sold 8,000 shares. The insider’s holdings dropped to 194,394 shares worth approximately $4.38 million following the completion of this transaction.
Also, Accardi Mario Alberto purchased 8,000 shares, netting a total of over 200,000 in proceeds.
Before that, HUSSAIN IQBAL J had sold 6,000 shares from its account. In a trade valued at $134,439, the General Counsel traded Centessa Pharmaceuticals plc ADR shares for $22.41 each. Upon closing the transaction, the insider’s holdings decreased to 6,000 shares, worth approximately $2.37 million.
As published in their initiating research note from Stephens on October 28, 2025, Centessa Pharmaceuticals plc ADR [CNTA] has been an Overweight and the price target has been revised to $35. Analysts at Wells Fargo started covering the stock with ‘”an Overweight”‘ outlook in a report released in early September. Earlier on July 21, 2025, Truist initiated its rating. Their recommendation was “a Buy” for CNTA stock.
Analyzing CNTA Stock Performance
On last trading session, Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] plunged -5.14% to $22.52. The stock’s lowest price that day was $17.05, but it reached a high of $22.885 in the same session. During the last five days, there has been a drop of approximately -6.09%. Over the course of the year, Centessa Pharmaceuticals plc ADR shares have jumped approximately 43.71%. Shares of the company reached a 52-week high of $25.42 on 11/03/25 and a 52-week low of $9.60 on 04/09/25.
Support And Resistance Levels for Centessa Pharmaceuticals plc ADR (CNTA)
According to the 24-hour chart, there is a support level at 18.74, which, if violated, would cause prices to drop to 14.96. In the upper region, resistance lies at 24.61. The next price resistance is at 26.69. RSI (Relative Strength Index) is 45.10 on the 14-day chart, showing neutral technical sentiment.
Is Centessa Pharmaceuticals plc ADR subject to short interest?
Stocks of Centessa Pharmaceuticals plc ADR saw a sharp steep in short interest on 2025-10-15 dropping by -0.31 million shares to 5.2 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 5.51 million shares. A decline of -5.99% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.01 of the overall float, the days-to-cover ratio (short ratio) decline to 5.01.
Which companies own the most shares of Centessa Pharmaceuticals plc ADR (CNTA)?
In terms of Centessa Pharmaceuticals plc ADR share price expectations, FactSet research, analysts set an average price target of 30 in the next 12 months, up nearly 26.37% from the previous closing price of $23.74. Analysts anticipate Centessa Pharmaceuticals plc ADR stock to reach 35 by 2025, with the lowest price target being 6. In spite of this, 6 analysts ranked Centessa Pharmaceuticals plc ADR stock as Buy at the end of 2025. On May 28, 2025, Needham assigned a price target of “a Buy” to the stock and initiated coverage with a $35.
